Mendra key facts
as of Oct 2026- Operator of an AI-native biopharmaceutical company intended to modernize the development and commercialization of rare disease therapies, accelerating access to life-saving treatments for underserved…
- Mendra is valued at approximately $128.0M as of Oct 2026 (last reported valuation).
- It has raised $82.0M; the latest was Early Stage VC ($82.0M) in Jan 2026.
- Notable investors include 8VC, Lux Capital, OrbiMed, Wing Venture Capital, 5AM Ventures — 6 tracked in total.
- Status: Privately Held (backing).
Mendra's last reported valuation, Jan 2026. Nothing priced has surfaced since.
- ·Watch Mendra: the Monday email on marks, rounds and moves
Mendra funding rounds
No funding rounds for Mendra are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Mendra valuation
Mendra's last reported valuation was $128 million in Jan 2026. No priced round, secondary trade or fund mark has surfaced since.
Mendra investors
6 investors are on record for Mendra, including 8VC, Lux Capital, OrbiMed and Wing Venture Capital. By type, the record holds 4 venture capital firms, 1 private equity firm and 1 growth equity firm.
About Mendra
Operator of an AI-native biopharmaceutical company intended to modernize the development and commercialization of rare disease therapies, accelerating access to life-saving treatments for underserved patients worldwide. The company's AI-driven platform integrates deep rare disease expertise with advanced capabilities in asset selection, patient identification, clinical trial enrollment and global commercialization, enabling customers to benefit from faster timelines, improved execution and expanded access to breakthrough therapies.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2025
- Employees
- 4
- Website
- mendra.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.